JPMorgan Chase & Co. Sells 7,591 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

JPMorgan Chase & Co. decreased its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 1.3% during the third quarter, Holdings Channel reports. The fund owned 566,130 shares of the company’s stock after selling 7,591 shares during the period. JPMorgan Chase & Co.’s holdings in Myriad Genetics were worth $15,506,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Point72 Hong Kong Ltd bought a new position in Myriad Genetics in the third quarter valued at about $32,000. GAMMA Investing LLC lifted its holdings in Myriad Genetics by 34.1% in the third quarter. GAMMA Investing LLC now owns 1,620 shares of the company’s stock valued at $44,000 after acquiring an additional 412 shares during the period. Point72 DIFC Ltd bought a new position in Myriad Genetics in the second quarter valued at about $60,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Myriad Genetics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock valued at $87,000 after acquiring an additional 583 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Myriad Genetics in the second quarter valued at about $82,000. Institutional investors own 99.02% of the company’s stock.

Analysts Set New Price Targets

MYGN has been the topic of several recent research reports. StockNews.com raised Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Thursday. Leerink Partners downgraded Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $30.00 to $21.00 in a research note on Monday, December 9th. Morgan Stanley decreased their price objective on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Monday, November 18th. Piper Sandler decreased their price objective on Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th. Finally, UBS Group initiated coverage on Myriad Genetics in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $18.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Myriad Genetics has a consensus rating of “Hold” and an average target price of $24.27.

Myriad Genetics Stock Up 0.3 %

Shares of MYGN opened at $14.83 on Friday. The business’s 50 day moving average is $15.19 and its 200 day moving average is $22.35. The company has a market capitalization of $1.35 billion, a PE ratio of -11.41 and a beta of 1.89. Myriad Genetics, Inc. has a 12-month low of $12.87 and a 12-month high of $29.30. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.